The global Rivaroxaban Market is estimated to be valued at US$ 14.89 million in 2021 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Rivaroxaban is an oral anticoagulant used to prevent and treat blood clots. It is marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian